Prevnar is a pneumococcal conjugate vaccine that protects against infections caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, meningitis, bloodstream infections, and ear infections. The current version, Prevnar 20, covers 20 different strains of the bacterium and is approved for anyone from 6 weeks of age through adulthood.
What Prevnar Protects Against
Streptococcus pneumoniae isn’t a single organism. It comes in dozens of strains (called serotypes), and Prevnar 20 targets 20 of the most dangerous ones. These strains cause a range of illnesses, from relatively common pneumonia to life-threatening invasive disease where bacteria enter the bloodstream or the lining of the brain. In young children, pneumococcal bacteria are also a leading cause of ear infections and sinus infections.
Invasive pneumococcal disease is most dangerous at the extremes of age. Infants and adults over 65 face the highest risk of serious complications, which is why vaccination is routine for both groups.
How Conjugate Vaccines Work
The word “conjugate” in Prevnar’s name refers to the technology that makes it more effective than older pneumococcal vaccines. The bacterium’s outer coating is made of sugar molecules (polysaccharides) that the immune system can recognize, but sugars alone trigger a relatively weak, short-lived response. Older polysaccharide vaccines like Pneumovax 23 work this way: they activate a specific type of immune cell that produces antibodies without building strong long-term memory.
Prevnar solves this by chemically linking those sugar molecules to a protein carrier. This combination recruits a broader immune response, pulling in helper cells that create lasting memory. The result is a stronger initial antibody response and immune cells that remember the bacterium years later. This distinction matters most for infants, whose immune systems don’t respond well to plain polysaccharide vaccines at all.
How Well It Works
In the landmark clinical trial among adults 65 and older who had never received a pneumococcal vaccine, the conjugate vaccine reduced invasive pneumococcal disease (the most severe form) by 75%. It cut cases of pneumococcal pneumonia that didn’t involve bloodstream infection by 45%. Real-world studies after the vaccine’s widespread use have confirmed effectiveness against invasive disease in the range of 47% to 68%, with similar numbers for pneumonia.
These numbers are substantially better than those for the older polysaccharide vaccine, which showed a pooled effectiveness of 45% against invasive disease and only about 18% against pneumonia across multiple studies. The conjugate vaccine’s advantage comes from its stronger, longer-lasting immune response.
Prevnar 20 vs. Pneumovax 23
Two types of pneumococcal vaccine exist for adults, and they work differently:
- Prevnar 20 (PCV20) is a conjugate vaccine covering 20 strains. It produces stronger immune memory and is given as a single intramuscular injection.
- Pneumovax 23 (PPSV23) is a polysaccharide vaccine covering 23 strains. It triggers a weaker immune response without the same lasting memory, though it covers three additional strains not in Prevnar 20.
For most adults, current recommendations favor Prevnar 20 as a single dose, which simplifies things considerably. Pneumovax 23 costs significantly less per dose (roughly $35 compared to $110 for Prevnar 20), but the stronger immune response from the conjugate vaccine generally makes it the preferred choice.
The Pediatric Schedule
For infants, Prevnar is given as a four-dose series at 2 months, 4 months, 6 months, and 12 to 15 months of age. This schedule is part of the routine childhood immunization program and has dramatically reduced rates of invasive pneumococcal disease in children since the first version of Prevnar was introduced in 2000.
Children who miss doses or start the series late can follow a catch-up schedule. The exact number of doses depends on the child’s age at the first vaccination.
Who Needs It as an Adult
All adults 65 and older are recommended to receive pneumococcal vaccination. For younger adults, certain health conditions move the timeline up. You’re considered at increased risk if you have any of the following:
- Immunocompromising conditions: HIV, sickle cell disease, congenital or acquired immune deficiency, a missing or nonfunctional spleen, or treatment with immunosuppressive drugs or radiation
- Chronic organ disease: chronic lung disease (including COPD, emphysema, and asthma), chronic heart disease (such as congestive heart failure, but not high blood pressure alone), chronic liver disease, chronic kidney failure, or nephrotic syndrome
- Other risk factors: diabetes, cochlear implants, cerebrospinal fluid leaks, alcoholism, or cigarette smoking
If any of these apply to you, vaccination is recommended regardless of age. People with immunocompromising conditions are at especially high risk because their bodies may struggle to fight off even common bacterial infections.
Common Side Effects
Prevnar’s side effects are typical of injectable vaccines. The most common is pain, redness, or swelling at the injection site. Fatigue, headache, muscle aches, and joint pain also occur frequently in adults. Infants may develop irritability, drowsiness, or a mild fever after their doses.
These reactions generally appear within a day or two and resolve on their own within 48 to 72 hours. Serious allergic reactions are rare, as with most vaccines.
Versions of Prevnar Over Time
The vaccine has expanded its coverage over the years. The original Prevnar, introduced in 2000, covered 7 strains. Prevnar 13, which replaced it in 2010, covered 13. The current Prevnar 20, approved in 2021 for adults and later extended to children, covers 20 strains. Each update added protection against strains that were causing the most disease in vaccinated populations, since bacteria not covered by the vaccine had gradually filled the ecological gap left by the suppressed strains.